Sign In
Buy ISRG
Intuitive Surgical Earnings Calls
| Release date | Apr 21, 2026 |
| EPS estimate | $2.12 |
| EPS actual | $2.50 |
| EPS Surprise | 17.92% |
| Revenue estimate | 2.619B |
| Revenue actual | 2.771B |
| Revenue Surprise | 5.81% |
| Release date | Jan 22, 2026 |
| EPS estimate | $2.27 |
| EPS actual | $2.53 |
| EPS Surprise | 11.45% |
| Revenue estimate | 2.763B |
| Revenue actual | 2.866B |
| Revenue Surprise | 3.75% |
| Release date | Oct 21, 2025 |
| EPS estimate | $1.99 |
| EPS actual | $2.40 |
| EPS Surprise | 20.60% |
| Revenue estimate | 2.406B |
| Revenue actual | 2.505B |
| Revenue Surprise | 4.10% |
| Release date | Jul 22, 2025 |
| EPS estimate | $1.93 |
| EPS actual | $2.19 |
| EPS Surprise | 13.47% |
| Revenue estimate | 2.351B |
| Revenue actual | 2.44B |
| Revenue Surprise | 3.77% |
Last 4 Quarters for Intuitive Surgical
Below you can see how ISRG performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Jul 22, 2025 |
| Price on release | $511.00 |
| EPS estimate | $1.93 |
| EPS actual | $2.19 |
| EPS surprise | 13.47% |
| Date | Price |
|---|---|
| Jul 16, 2025 | $512.64 |
| Jul 17, 2025 | $516.16 |
| Jul 18, 2025 | $518.62 |
| Jul 21, 2025 | $516.12 |
| Jul 22, 2025 | $511.00 |
| Jul 23, 2025 | $501.95 |
| Jul 24, 2025 | $488.61 |
| Jul 25, 2025 | $495.86 |
| Jul 28, 2025 | $493.95 |
| 4 days before | -0.320% |
| 4 days after | -3.34% |
| On release day | -1.77% |
| Change in period | -3.65% |
| Release date | Oct 21, 2025 |
| Price on release | $462.74 |
| EPS estimate | $1.99 |
| EPS actual | $2.40 |
| EPS surprise | 20.60% |
| Date | Price |
|---|---|
| Oct 15, 2025 | $435.61 |
| Oct 16, 2025 | $434.62 |
| Oct 17, 2025 | $446.13 |
| Oct 20, 2025 | $458.47 |
| Oct 21, 2025 | $462.74 |
| Oct 22, 2025 | $527.03 |
| Oct 23, 2025 | $551.30 |
| Oct 24, 2025 | $546.51 |
| Oct 27, 2025 | $551.25 |
| 4 days before | 6.23% |
| 4 days after | 19.13% |
| On release day | 13.89% |
| Change in period | 26.55% |
| Release date | Jan 22, 2026 |
| Price on release | $525.81 |
| EPS estimate | $2.27 |
| EPS actual | $2.53 |
| EPS surprise | 11.45% |
| Date | Price |
|---|---|
| Jan 15, 2026 | $541.34 |
| Jan 16, 2026 | $535.00 |
| Jan 20, 2026 | $527.44 |
| Jan 21, 2026 | $523.69 |
| Jan 22, 2026 | $525.81 |
| Jan 23, 2026 | $523.99 |
| Jan 26, 2026 | $528.81 |
| Jan 27, 2026 | $525.04 |
| Jan 28, 2026 | $522.04 |
| 4 days before | -2.87% |
| 4 days after | -0.717% |
| On release day | -0.346% |
| Change in period | -3.57% |
| Release date | Apr 21, 2026 |
| Price on release | $451.29 |
| EPS estimate | $2.12 |
| EPS actual | $2.50 |
| EPS surprise | 17.92% |
| Date | Price |
|---|---|
| Apr 15, 2026 | $468.36 |
| Apr 16, 2026 | $458.08 |
| Apr 17, 2026 | $469.21 |
| Apr 20, 2026 | $465.60 |
| Apr 21, 2026 | $451.29 |
| Apr 22, 2026 | $483.62 |
| Apr 23, 2026 | $478.82 |
| Apr 24, 2026 | $482.22 |
| Apr 27, 2026 | $470.99 |
| 4 days before | -3.64% |
| 4 days after | 4.37% |
| On release day | 7.16% |
| Change in period | 0.562% |
Intuitive Surgical Earnings Call Transcript Summary of Q1 2026
Intuitive reported a strong Q1 2026: total procedures grew 17% (da Vinci +16%, Ion +39%), revenue rose 23% to $2.77B, recurring revenue was $2.4B (86% of total), non-GAAP operating margin was 39%, and non-GAAP EPS was $2.50. U.S. and Europe were strong, while China and Japan remained challenged (China: low tenders, pricing pressure; Japan: fewer placements but recent reimbursement improvements). Product momentum: da Vinci 5 adoption continues (232 placements this quarter; ~1,500 installed worldwide), Force Feedback instrument clearances expanded with broader availability expected in 2H, SP platform procedures grew 68% with continued early adoption, and Ion placements and clinical data support improved lung cancer diagnosis. Capital placements: 431 da Vinci systems and 52 Ion systems in Q1; increased leasing adoption. Cash and investments ended at $8B after $1.1B stock repurchases and a regional distributor acquisition. Management raised full-year da Vinci procedure growth guidance to 13.5%–15.5% and updated 2026 non-GAAP gross margin guidance to 67.5%–68.5% and operating expense growth to 11%–14%. Company reiterated strategic priorities: global platform expansion, procedure adoption, manufacturing scale & quality, and continued innovation (digital/AI, telesurgery, ROSE/EBUS for lung). Management also disclosed and contained a Q1 cybersecurity incident with no material operational or financial impact.
